Exploring Impact of Mutations in Non-Brca DNA Damage Response (DDR) and Non-Ddr Genes on Efficacy in Phase III EMBRACA Study of Talazoparib (TALA) in Patients (pts) with Germline BRCA1/2 Mutated (gbrcam) HER2-negative (HER2-) Advanced Breast Cancer (ABC).
JOURNAL OF CLINICAL ONCOLOGY（2020）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined